Nephro-Urology Monthly

Published by: Kowsar

Gender Difference in Cisplatin-Induced Nephrotoxicity in a Rat Model

Amr Ahmed EL-Arabey 1 , *
Author Information
1 Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt
Article information
  • Nephro-Urology Monthly: March 01, 2015, 7 (2); e23595
  • Published Online: February 19, 2015
  • Article Type: Letter
  • Received: September 13, 2014
  • Accepted: October 4, 2014
  • DOI: 10.5812/numonthly.23595

To Cite: EL-Arabey A A. Gender Difference in Cisplatin-Induced Nephrotoxicity in a Rat Model, Nephro-Urol Mon. 2015 ; 7(2):e23595. doi: 10.5812/numonthly.23595.

Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Gender difference in Cisplatin-induced nephrotoxicity in a rat model: greater intensity of damage in male than female. Nephrourol Mon. 2013; 5(3): 818-21[DOI][PubMed]
  • 2. Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F, Nasri H, Talebi A, et al. Vitamin E, Vitamin C, or Losartan Is Not Nephroprotectant against Cisplatin-Induced Nephrotoxicity in Presence of Estrogen in Ovariectomized Rat Model. Int J Nephrol. 2012; 2012: 284896[DOI][PubMed]
  • 3. Carraro-Eduardo JC, Oliveira AV, Carrapatoso ME, Ornellas JF. Effect of sex hormones on gentamicin-induced nephrotoxicity in rats. Braz J Med Biol Res. 1993; 26(6): 653-62[PubMed]
  • 4. Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen Abolishes Protective Effect of Erythropoietin against Cisplatin-Induced Nephrotoxicity in Ovariectomized Rats. ISRN Oncol. 2012; 2012: 890310[DOI][PubMed]
  • 5. Safari T, Nematbakhsh M, Hilliard LM, Evans RG, Denton KM. Sex differences in the renal vascular response to angiotensin II involves the Mas receptor. Acta Physiol (Oxf). 2012; 206(2): 150-6[DOI][PubMed]
  • 6. Hilliard LM, Nematbakhsh M, Kett MM, Teichman E, Sampson AK, Widdop RE, et al. Gender differences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor. Hypertension. 2011; 57(2): 275-82[DOI][PubMed]
  • 7. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985; 249(4 Pt 2)-6[PubMed]
  • 8. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007; 334(2): 115-24[DOI][PubMed]
  • 9. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993; 67(6): 1171-6[PubMed]
  • 10. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22): 14298-302[DOI][PubMed]
  • 11. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004; 66(4): 817-23[DOI][PubMed]
  • 12. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009; 296(3)-11[DOI][PubMed]
  • 13. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005; 70(12): 1823-31[DOI][PubMed]
  • 14. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004; 66(1): 196-202[DOI][PubMed]
  • 15. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002; 13(4): 866-74[PubMed]
  • 16. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005; 167(6): 1477-84[DOI][PubMed]
  • 17. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010; 176(3): 1169-80[DOI][PubMed]
  • 18. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009; 86(4): 396-402[DOI][PubMed]
  • 19. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y, et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett. 1999; 461(3): 339-42[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments